Trial Profile
Efficacy of eribulin mesylate combined with carboplatin in patients with advanced triple-negative breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2016
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Carboplatin
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 11 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology